Shares of Fannie Mae and Freddie Mac surged more than 30% on Monday after billionaire investor Bill Ackman, the founder of Pershing Square Capital Management, said on X that the mortgage-financing giants are “stupidly cheap” and could potentially rise tenfold, according to CNBC. The upbeat rhetoric around the government-sponsored enterprises helped lift sentiment in a session where a mix of earnings updates, regulatory headlines and strategic moves kept traders oscillating between risk-on and risk-off postures.
Among other notable moves, Boston Scientific tumbled more than 9% after Raymond James cut estimates and downgraded the medical device maker to outperform from strong buy, citing weakening trends in its core growth areas. In contrast, Palo Alto Networks rose more than 7% after CEO Nikesh Arora disclosed that he purchased $10 million worth of shares on the open market over the prior week. United Therapeutics climbed nearly 13%, marking a 52-week high, on positive Phase 3 results for Tyvaso, its leading therapy, and plans to seek FDA priority review to expand the drug’s label to include idiopathic pulmonary fibrosis, a progressive lung disease.
In the broader asset-management sphere, the Department of Labor’s proposed rule to allow 401(k) plans to more readily include alternative assets such as cryptocurrency, real estate and private market investments lifted shares of alternative-asset managers. Blackstone and Carlyle posted gains of more than 4%, while Blue Owl and Apollo Global rose more than 3%.
On the other side of the ledger, Sysco slumped more than 11% after it agreed to acquire Jetro Restaurant Depot for an enterprise value of $29.1 billion. The deal is expected to close in Sysco’s fiscal third quarter of 2027 and the company described the transaction as immediately accretive, but investors focused on the debt load associated with the acquisition. Avis slipped more than 3% after a recent blockbuster run, as traders unlocked profits following a surge of roughly 48% last week amid the airport-shipment disruption narrative tied to the Department of Homeland Security funding impasse.
Alcoa rallied more than 9% as aluminum prices rose over 4.5% after reports that critical infrastructure for the metal in the Middle East was struck by missile activity in the region. In the cybersecurity space, CrowdStrike rose more than 4% after analysts publicly backed the name. Wolfe Research upgraded the stock to outperform, arguing that the company stands to benefit from rising cyber-risk exposure tied to increased digital adoption and AI integration, while Morgan Stanley named it a top pick. The stock had been down more than 21% in 2026 on concerns that artificial intelligence could erode demand for traditional cybersecurity offerings.
According to CNBC, the afternoon picture reflected a blend of idiosyncratic company news and larger regulatory and macro themes, with investors parsing which headlines could translate into durable earnings power versus those likely to fade.
Key takeaways
- Fannie Mae and Freddie Mac up more than 30% after Ackman called the stocks “stupidly cheap” and suggested a potential tenfold upside.
- Regulatory shifts supported alternative-asset managers, sending Blackstone, Carlyle, Blue Owl and Apollo Global higher.
- Selective earnings and guidance moves stood out: United Therapeutics surged on positive Phase 3 data and a potential FDA label expansion; Boston Scientific fell on a downgrade and dimmer growth trends.
- Corporate transactions weighed on risk sentiment: Sysco’s acquisition deal spurred debt concerns despite near-term accretion signals.
- Tech and cyber names extended gains on upgrades and positive sentiment around AI-related risk dynamics, with CrowdStrike advancing after analyst support.
What drove the move
At the core of the session’s volatility were a handful of headline-driven catalysts. Ackman’s comments about Fannie Mae and Freddie Mac introduced a highly speculative, sentiment-driven bid into a space that has traded under heightened regulatory and political scrutiny for years. The notion of a potential tenfold upside, while not grounded in any formal forecast, fed a narrative of mispriced risk in this corner of the market, according to CNBC’s reporting team.
Separately, a regulatory development in the form of the Department of Labor’s proposed rule for 401(k) plan construction created a positive backdrop for asset managers that can broaden access to alternative investments. The prospect of broader allocation to non-traditional assets tends to support the revenue mix for large alternative managers, and the early reaction was constructive for Blackstone, Carlyle, Blue Owl and Apollo Global, CNBC noted.
Company-specific momentum also played a role. United Therapeutics’ Phase 3 results for Tyvaso provided a bullish read on its growth trajectory, with the company signaling a path to a priority FDA review to expand Tyvaso’s label to idiopathic pulmonary fibrosis. The update plus a 52-week high added to a trading narrative that favors healthcare innovators with late-stage data leverage.
Meanwhile, several names experienced downgrades or softening guidance. Boston Scientific faced a hit after Raymond James trimmed estimates below consensus and shifted the rating dynamic, underscoring how mixed growth signals in a capital-intensive device landscape can catalyze outsized downside in the near term.
Market reaction
The afternoon session illustrated a bifurcated market where high-beta pockets rallied on optimistic headlines while other areas gave back some ground on caution around leverage and growth trajectories. The financials-linked surge in the GSE group — Fannie Mae and Freddie Mac — stood out as one of the day’s most dramatic moves, reflecting a rare confluence of speculative fervor around mortgage-financing backstops and the potential for meaningful revaluation in an environment where policy and fiscal debates remain fluid.
Across sectors, tech equities benefited from defense-led upgrades and risk-on sentiment around cybersecurity resilience in an increasingly AI-enabled threat landscape. Palo Alto Networks’ gain plus the CrowdStrike upgrade and price action illustrate investors’ willingness to reward exposure to advanced threat protection, even as the broader tech space remains sensitive to interest-rate expectations and regulatory chatter.
On the downside, the Sysco deal added a debt- and capital allocation tilt to the day’s narrative. While management framed the transaction as immediately accretive, investors focused on how the financing will be structured and the longer-term implications for Sysco’s leverage profile. The Avis move also underscored profit-taking dynamics after a sharp rally tied to external disruption narratives at U.S. airports and related consumer demand signals.
What analysts are saying
Analysts’ take on the most active names this session remained mixed, with a notable emphasis on risk management and upside potential. Wolfe Research’s upgrade of CrowdStrike to outperform was cited by CNBC as a catalyst for renewed conviction around CrowdStrike’s ability to monetize increased cyber-risk postures and AI-enabled threat landscapes, suggesting a more durable growth trajectory than previously feared. Morgan Stanley’s designation of CrowdStrike as a top pick reinforced the thesis that the company could outperform amid heightened digital risk and regulatory complexity.
For Boston Scientific, the downgrade from Raymond James highlighted the current weakness in several key growth areas and suggested limited near-term catalysts that could alleviate the revenue shortfall. By contrast, United Therapeutics’ data-driven optimism around Tyvaso has positioned the stock as a potential beneficiary of broader lung-disease treatment pipelines and regulatory movement, according to the session’s read on the Phase 3 results and the FDA review plan.
Bigger picture
The session’s price action sits at the intersection of idiosyncratic news and broader macro themes. The DoL rulemaking signals a possible shift in how retirement portfolios can access non-traditional assets, a change that could gradually reshape the revenue prospects for major alternative-asset managers. If implemented, the rule could attract more capital into real estate, private markets, and even certain crypto exposures within tax-advantaged accounts, potentially supporting multiple stocks in that subsector over the medium term.
Beyond regulatory headlines, Ackman’s comments highlight a persistent theme about market mispricing and the outsized volatility that accompanies high-conviction calls from influential investors. While such calls can catalyze rapid moves, they also invite heightened scrutiny around valuation, risk tolerance and potential pullbacks if macro data or policy guidance disappoints. The mixed bag of results across earnings-driven, regulatory, and strategic news underscores a market environment where sector-by-sector narratives drive dispersion rather than uniform moves across risk assets.
Investors are also weighing the AI and cybersecurity dynamic more broadly. CrowdStrike’s positive reception underlines a belief that AI-driven threat environments will elevate the importance of endpoint security and threat intelligence, potentially supporting premium multiples for leading players even as some AI-related concerns dampened supplies earlier in the year. The healthcare and infrastructure-related stories, meanwhile, remind markets that pipeline progress and regulatory timing can deliver outsized moves relative to near-term earnings prints.
According to CNBC, the trading day’s moves should be read as a blend of one-off headlines and longer-running themes: the potential recalibration of asset-class exposure via retirement-plan rules, the ongoing re-evaluation of mortgage-financing equities in a politically sensitive space, and the ongoing demand for cybersecurity resilience in an AI-augmented world.
What to watch next remains clear. Investors will monitor any further developments on the DoL rule and its practical implementation for 401(k) plans, the regulatory stance around Fannie Mae and Freddie Mac, and any additional data points or company updates that could corroborate the current swing in risk appetite. Earnings reports and guidance from key players across financials, healthcare, technology and consumer services will also shape the tone for the coming weeks, as markets try to balance policy uncertainty with the appeal of value and growth under new narrative hooks.
In sum, the session delivered a reminder that price action can be driven as much by headlines and policy shifts as by fundamentals. For traders and longer-term investors, the lesson remains the same: identify where changes in regime or incentives could alter risk-reward, and be prepared for rapid pivots as new information arrives.
